The dependency of embryonal‐like HB tumor cells on hexokinase 1, as well as the GLUT3, LDHB, and G6PC staining on tumor sections could be used as novel biomarkers to highlight metabolic variation in HB and guide future therapies based on metabolic vulnerabilities. This evidence concerns the gene LDHB and neoplasm.